CPD Activities

Recombinant Human Thrombomodulin in Patients with Severe Sepsis and Septic Shock, complicated by Coagulopathy


Recombinant Human Thrombomodulin in Patients with Severe Sepsis and Septic Shock, complicated by Coagulopathy


Starting on :12:30 PM 02 April, 2015 Venue:Aga Khan University Hospital Nairobi
Ending on :02:00 PM 02 April, 2015 Max Credits:3.00
Moderator:No Activity Moderator Activity Cost: Free Order

Presenters

1. Dr. David Da Costa
MD, MSc Clinical Tropical Medicine PhD in Infectious Diseases Immunology

Description

a.       An overview of Thrombomodulin, its mechanism of action, and its role in the coagulation cascade. Learning points include the role of Disseminated Intravascular Coagulation (DIC) in mortality from sepsis.

b.      A brief review of Phase 2b study data for Recombinant Thrombomodulin in Severe Sepsis with Coagulopathy.

c.       An over view of Thrombin generation mediators and inflammatory and hemostatic biomarkers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.

d.      An review of the protocol for an ongoing Phase 3 study of Recombinant Thrombomodulin in Severe Sepsis with Coagulopathy.

e.      An overview of tools to facilitate subject enrollment in the Phase 3 study: A screening tool and a laboratory alert tool.


Objectives

a.       An overview of Thrombomodulin, its mechanism of action, and its role in the coagulation cascade. Learning points include the role of Disseminated Intravascular Coagulation (DIC) in mortality from sepsis.

b.      A brief review of Phase 2b study data for Recombinant Thrombomodulin in Severe Sepsis with Coagulopathy.

c.       An over view of Thrombin generation mediators and inflammatory and hemostatic biomarkers in sepsis-associated coagulopathy and their modulation by recombinant thrombomodulin.

d.      An review of the protocol for an ongoing Phase 3 study of Recombinant Thrombomodulin in Severe Sepsis with Coagulopathy.

e.      An overview of tools to facilitate subject enrollment in the Phase 3 study: A screening tool and a laboratory alert tool.





Online Register